Tatiana katerina Galpérine

Dr. Tatiana katerina Galpérine

Infectious disease, Lausanne University Hospital (CHUV), Lausanne, Vaud, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
FCF. Caron
F. Caron
TGTatiana katerina Galpérine
Tatiana katerina Galpérine
CFC. Flateau
C. Flateau
RAR. Azria
R. Azria
SBS. Bonacorsi
S. Bonacorsi
MEM. Etienne
M. Etienne

20 August 2019 in BMJ
Verified
Journal Article
Closed access
PDF file
BGBenoit Guery
Benoit Guery
TGTatiana katerina Galpérine
Tatiana katerina Galpérine
FBFrédéric Barbut
Frédéric Barbut
Clostridioides difficile(formerlyClostridium) is a major cause of healthcare associated diarrhea, and is increasingly present in the community. Historically,C difficileinfection was considered easy to diagnose and treat. Over the past two decades, however, diagnostic techniques have changed in line with a greater understanding of the physiopathology ofC difficileinfection and the use of new therapeutic molecules. The evolution of diagnosis showed there was an important under- and misdiagnosis ofC difficileinfection, emphasizing the importance of algorithms recommended by European and North American infectious diseases societies to obtain a reliable diagnosis. Previously, metronidazole was considered the reference drug to treatC difficileinfection, but more recently vancomycin and other newer drugs are shown to have higher cure rates. Recurrence of infection represents a key parameter in the evaluation of new drugs, and the challenge is to target the right population with the adapted therapeutic molecule. In multiple recurrences, fecal microbiota transplantation is recommended. New approaches, including antibodies, vaccines, and new molecules are already available or in the pipeline, but more data are needed to support the inclusion of these in practice guidelines. This review aims to provide a baseline for clinicians to understand and stratify their choice in the diagnosis and treatment ofC difficileinfection based on the most recent data available.

1 July 2007 in Journal of Infection
Verified
Journal Article
Closed access
TGTatiana katerina Galpérine
Tatiana katerina Galpérine
CCCécile Cazorla
Cécile Cazorla
EBElodie Blanchard
Elodie Blanchard
FBFrançoise Boineau
Françoise Boineau
JRJean-Marie Ragnaud
Jean-Marie Ragnaud
DNDidier Neau
Didier Neau

19 July 2021 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
SBSimon Mark Dahl Baunwall
Simon Mark Dahl Baunwall
ETElisabeth M Terveer
Elisabeth M Terveer
JDJens Frederik Dahlerup
Jens Frederik Dahlerup
CEChristian Erikstrup
Christian Erikstrup
PAPerttu Arkkila
Perttu Arkkila
CHChristian Lodberg Hvas
Christian Lodberg Hvas
Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for FMT in Europe. We invited all hospital-based FMT centres within the European Council member states to answer a web-based questionnaire covering their clinical activities, organisation, and regulation of FMT in 2019. Responders were identified from trials registered at clinicaltrials.gov and from the United European Gastroenterology (UEG) working group for stool banking and FMT. In 2019, 31 FMT centres from 17 countries reported a total of 1,874 (median 25, quartile 10–64) FMT procedures; 1,077 (57%) with Clostridioides difficile infection (CDI) as indication, 791 (42%) with experimental indications, and 6 (0•3%) unaccounted for. Adjusted to population size, 0•257 per 100,000 population received FMT for CDI and 0•189 per 100,000 population for experimental indications. With estimated 12,400 (6,100–28,500) annual cases of multiple, recurrent CDI and indication for FMT in Europe, the current European FMT activity covers approximately 10% of the patients with indication. The participating centres demonstrated high safety standards and adherence to international consensus guidelines. Formal or informal regulation from health authorities was present at 21 (68%) centres. FMT is a widespread routine treatment for multiple, recurrent CDI and an experimental treatment. Embedded within hospital settings, FMT centres operate with high standards across Europe to provide safe FMT. A significant gap in FMT coverage suggests the need to raise clinical awareness and increase the FMT activity in Europe by at least 10-fold to meet the true, indicated need. NordForsk under the Nordic Council and Innovation Fund Denmark (j.no. 8056–00006B).

1 December 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
LMLinda Mueller
Linda Mueller
AMAmandine Masseron
Amandine Masseron
GPGuy Prod’hOm
Guy Prod’hOm
TGTatiana katerina Galpérine
Tatiana katerina Galpérine
Gilbert GREUBGilbert GREUB
Gilbert GREUB
PNPatrice Nordmann
Patrice Nordmann
A novel KPC variant, KPC-41, was identified in a Klebsiella pneumoniae clinical isolate from Switzerland. This β-lactamase possessed a 3-amino-acid insertion (Pro-Asn-Lys) located between amino acids 269 and 270 compared to the KPC-3 amino acid sequence. Cloning and expression of the blaKPC-41 gene in Escherichia coli, followed by determination of MIC values and kinetic parameters, showed that KPC-41, compared to those of KPC-3, has an increased affinity to ceftazidime and a decreased sensitivity to avibactam, leading to resistance to ceftazidime-avibactam once produced in K. pneumoniae. Furthermore, KPC-41 exhibited a drastic decrease of its carbapenemase activity. This report highlights that a diversity of KPC variants conferring resistance to ceftazidime-avibactam already circulate in Europe.

1 March 2016 in Digestive and Liver Disease
Verified
Journal Article
Closed access
HSHarry Sokol
Harry Sokol
TGTatiana katerina Galpérine
Tatiana katerina Galpérine
NKNathalie Kapel
Nathalie Kapel
PBPierre Bourlioux
Pierre Bourlioux
PSPhilippe SEKSIK
Philippe SEKSIK
FZFrank Zerbib
Frank Zerbib